# v1 Medication Guidance Content

**Simple medication reference lists + NZF integration messaging**

---

## Page Placement

This content appears on the main page (`page.tsx`) as a **collapsible accordion section** below the Interactive Checklist.

**Section heading:** "Medication Reference Guide"

**Location:** Between the checklist and the "Evidence & Resources" section

---

## Content Structure

### Main Accordion: "Medication Reference Guide"

**Opening state:** Collapsed (user clicks to expand)

**Intro text (when expanded):**

> This is a quick reference guide with common medication examples. For complete, up-to-date monitoring requirements, always check the New Zealand Formulary (NZF).
> 
> **â†’ Open NZF:** [https://nzf.org.nz](https://nzf.org.nz)

---

## Sub-Accordion 1: "Generally NOT Suitable for 12 Months"

**Why NOT suitable:** Requires monitoring more often than annually

### Controlled Drugs (Legal Exclusion)

**Maximum duration:** 1-3 months (law, not clinical judgment)

| Class | Max Duration | Examples |
|-------|--------------|----------|
| **Class B** | 1 month | Morphine, oxycodone, fentanyl, methadone, methylphenidate, dexamphetamine |
| **Class C** | 3 months | Tramadol, codeine (prescription strength), diazepam, lorazepam, clonazepam, zopiclone, zolpidem |

**Source:** Misuse of Drugs Act 1975

---

### High-Risk Medications Requiring Regular Monitoring

**Typical maximum:** 3 months

**Examples:**

- **Warfarin** - INR monitoring (weekly to monthly depending on stability)
- **Lithium** - Levels 3-monthly, renal + thyroid function 3-6 monthly
- **Digoxin** - Levels + renal function 3-6 monthly, ECG annually
- **Methotrexate** - FBC + LFTs monthly initially, then 2-3 monthly
- **Azathioprine** - FBC + LFTs monthly initially, then 3-monthly
- **Amiodarone** - TFTs + LFTs 6-monthly, CXR + ECG annually
- **Sodium valproate** - LFTs + FBC 6-monthly
- **Carbamazepine** - FBC + LFTs + Na+ 6-monthly
- **Insulin** - Regular dose adjustments needed

**Why unsuitable:** These medications need regular blood tests or monitoring that can't wait 12 months.

**â†’ Check NZF** for specific monitoring schedules and dose adjustments.

---

## Sub-Accordion 2: "Requires Individual Assessment"

**Why individual:** Suitability depends on patient parameters (eGFR, age, etc.)

**Action:** Check patient's specific values before deciding duration.

### Common Examples:

**Metformin**
- eGFR >45: Generally suitable for 12 months
- eGFR 30-45: Max 6 months (dose reduction may be needed)
- eGFR <30: Contraindicated
- **â†’ Check NZF** for exact dosing adjustments

**ACE Inhibitors / ARBs** (enalapril, lisinopril, irbesartan, losartan)
- eGFR â‰¥60: Generally suitable for 12 months
- eGFR 45-59: Consider 6-12 months
- eGFR 30-44: Max 6 months
- eGFR <30: Max 3-6 months, specialist input
- **â†’ Check NZF** for renal monitoring frequency

**DOACs** (dabigatran, rivaroxaban, apixaban)
- CrCl â‰¥50: Generally suitable for 12 months (varies by drug)
- CrCl <50: Shorter durations or dose adjustments needed
- **â†’ Check NZF** - thresholds differ by DOAC type

**Sulfonylureas** (gliclazide, glipizide)
- Age <70 + eGFR >60: Generally suitable for 12 months
- Age â‰¥70 OR eGFR <60: Consider 6 months (hypoglycaemia risk)
- **â†’ Check NZF** for renal dose adjustments

**NSAIDs** (naproxen, diclofenac, celecoxib)
- Young + normal renal function: 6-12 months if chronic use unavoidable
- With ACEi/ARB ("double whammy"): Max 6 months
- With ACEi/ARB + diuretic ("triple whammy"): Max 3 months
- **â†’ Check BPAC** for triple whammy guidance

**Spironolactone**
- MAX 6 months even when stable (needs K+ monitoring at 1 week, 1 month, then 6-monthly)
- **â†’ Check NZF** for monitoring protocol

**Allopurinol**
- eGFR >60: Generally suitable for 12 months
- eGFR <60: Consider 6 months (dose reduction needed)
- **â†’ Check NZF** for dose adjustments

**Other individual-assessment medications:**
- SGLT-2 inhibitors (empagliflozin) - eGFR-dependent
- Gabapentin/pregabalin - eGFR-dependent
- Bisphosphonates - eGFR-dependent
- Loop diuretics - Max 6 months (electrolyte monitoring)
- Levothyroxine - 12 months OK if dose stable 6+ months

**â†’ Always check NZF** for current monitoring requirements and dose adjustments.

---

## Sub-Accordion 3: "Generally Suitable for 12 Months"

**If patient stable:** These medications typically require only annual monitoring.

**Note:** "Generally suitable" does NOT mean "automatically 12 months for everyone." Patient must still be stable (condition controlled, dose unchanged).

### Common Examples:

**Cardiovascular:**
- Statins (atorvastatin, simvastatin, rosuvastatin)
- Calcium channel blockers (amlodipine, felodipine)
- Beta blockers (metoprolol, bisoprolol, atenolol)
- Aspirin (antiplatelet dose)

**Respiratory:**
- Inhaled corticosteroids (fluticasone, budesonide)
- ICS/LABA combinations (Seretide, Symbicort)
- LAMA (tiotropium)
- Salbutamol

**Gastrointestinal:**
- PPIs (omeprazole, esomeprazole)

**Hormonal:**
- Oral contraceptives (annual BP check)
- Levothyroxine (if dose stable)

**Mental Health:**
- SSRIs/SNRIs (fluoxetine, sertraline, citalopram, escitalopram, venlafaxine)
  - **Must have annual discussion** about ongoing need
- Mirtazapine

**Diabetes:**
- DPP-4 inhibitors (vildagliptin, sitagliptin)

**Other:**
- Calcium + Vitamin D
- Montelukast

**Typical annual monitoring:**
- BP (cardiovascular meds)
- Lipid profile (statins)
- TSH (levothyroxine)
- Spirometry (respiratory meds, if available)
- Inhaler technique check (respiratory meds)

**â†’ Check NZF** to confirm annual monitoring is sufficient for your patient.

---

## Important Notes Section

**Appears at bottom of accordion, always visible when expanded:**

### ðŸ”´ Important Notes:

1. **These are EXAMPLES, not comprehensive lists.** Many medications not listed here may be suitable for 12 months. Always check NZF.

2. **Lists are GUIDANCE, not rules.** You have full clinical discretion. A medication in "Generally Suitable" may need 6 months in a particular patient.

3. **NZF is the authoritative source.** These lists are simplified for quick reference. For dose adjustments, monitoring frequency, and contraindications, always check NZF.

4. **When in doubt:** Prescribe a shorter duration (3 or 6 months). You can always extend next time.

5. **6 months is completely acceptable.** RNZCGP recommended 6 months as safer than 12 months. Don't feel pressured to prescribe 12 months.

---

## "About NZF Integration" Callout Box

**Design:** Light blue background box, positioned at top of accordion (above sub-accordions)

### Content:

> **Why we link to NZF instead of listing all medications**
>
> The New Zealand Formulary is the gold-standard, authoritative source for medication information in NZ. It's updated monthly and includes:
> - Monitoring requirements
> - Dose adjustments for renal/hepatic impairment
> - Drug interactions
> - Contraindications
> - Latest safety alerts
>
> Rather than duplicate (and risk outdating) this information, we link directly to NZF so you always have current data.
>
> **We've requested API access from NZF** to integrate medication data directly into this tool. If approved, future versions will auto-populate monitoring requirements without leaving this page.
>
> **â†’ Open NZF in new tab:** [https://nzf.org.nz](https://nzf.org.nz)

---

## Disclaimer Text

**Appears at very bottom of accordion:**

**Disclaimer:** This medication reference is for educational purposes only and does not replace clinical judgment or official prescribing guidance. Always consult the New Zealand Formulary, Medsafe data sheets, and relevant clinical guidelines. Medication lists were compiled from RNZCGP guidance, BPAC resources, and clinical consensus as of February 2026.

---

## Visual Design Notes

### Accordion Hierarchy:

```
ðŸ“‹ Medication Reference Guide  [Click to expand â–¼]
  â”œâ”€ [Blue callout box: About NZF Integration]
  â”œâ”€ ðŸ”´ Generally NOT Suitable for 12 Months  [Click to expand â–¼]
  â”‚   â”œâ”€ Controlled Drugs (table)
  â”‚   â””â”€ High-Risk Medications (list)
  â”œâ”€ ðŸŸ¡ Requires Individual Assessment  [Click to expand â–¼]
  â”‚   â””â”€ Examples with criteria
  â”œâ”€ ðŸŸ¢ Generally Suitable for 12 Months  [Click to expand â–¼]
  â”‚   â””â”€ Examples by category
  â”œâ”€ [Important Notes section]
  â””â”€ [Disclaimer]
```

### Icons:
- Main accordion: ðŸ“‹ (clipboard)
- Sub-accordion 1: ðŸ”´ (red circle)
- Sub-accordion 2: ðŸŸ¡ (yellow circle)
- Sub-accordion 3: ðŸŸ¢ (green circle)

### Colors:
- Use subtle background colors matching existing site palette
- Don't use bright red/amber/green (we're avoiding "zone" language)
- Use icons + text labels for accessibility

---

## Mobile Considerations

- All accordions stack vertically
- Tables in "Controlled Drugs" should be horizontally scrollable on mobile
- NZF link buttons should be full-width on mobile (<640px)

---

## Copy-Paste Snippets for Implementation

### NZF Link Button:

```html
<a 
  href="https://nzf.org.nz" 
  target="_blank" 
  rel="noopener noreferrer"
  class="inline-flex items-center gap-2 rounded-lg bg-blue-600 px-4 py-2 text-white hover:bg-blue-700"
>
  Open NZF
  <svg><!-- external link icon --></svg>
</a>
```

### "Check NZF" Inline Link:

```html
<a 
  href="https://nzf.org.nz" 
  target="_blank" 
  rel="noopener noreferrer"
  class="font-medium text-primary hover:underline"
>
  â†’ Check NZF
</a>
```

---

**End of Content Specification**
